Table 4.
Nanoparticulate formulations stabilized with poloxamers.
| Polymer | Surfactant | NP Size (nm) |
PDI | Z-Potential (mV) |
Drug | EE or DL | Application | Reference |
|---|---|---|---|---|---|---|---|---|
| PCL | F-127, 2% | 167 | 0.188 | ~0 | Amphotericin | EE = 85% | Increase the solubility of the drug as treatment for Leishmania infections | [247] |
| Chitosan | F-127, 15% | 146 | N.A | 5.09 | Curcumin | EE = 61.7% | Development of effective delivery system with few side-effects | [250] |
| PCL | F-108, 50% F-127, 50% F-68, 50% |
182 184.7 698.4 |
0.2 0.28 0.88 |
–11.7 –1.6 –6.03 |
N.A | N.A | Evaluation of the effect of different surfactants | [251] |
| PLGA | F-68, 0.88% | 217.6 ± 8.6 | 0.171 | –23.35 ± 1.17 | Docetaxel | EE = 88% | Development of a delivery system for breast cancer chemotherapy | [252] |
| PLGA | F-68, 0.5% | 160–170 | 0.051 ± 0.012 | −20.5 ± 0.069 | N.A | N.A | Evaluation of the effect of poloxamer as surfactant | [253] |
| PCL/F-68 | PVA, 0.05% | 201.7 ± 10.1 | 0.096 | –12.50 ± 0.86 | Docetaxel | EE = 69.1% DL = 10% |
Evaluation of the increased level of uptake NP due to F-68 presence | [254] |
| PCL | F-68, 2% | 149.9 ± 2.2 | 0.087 ± 0.05 | N.A | Curcumin | EE = 96 ± 0.95% DL = 4.9 ± 0.7% |
Development of a potential alternative treatment for neuronal diseases based on curcumin |
[244] |
| PS | L61, F-68, F-108, L121, F-127 |
97 ± 1, 105 ± 1, 110, 100 ± 2, 108 ± 1 |
0.01, 0.03, 0.02, 0.02, 0.02 |
–42 ± 1, –26 ± 2, –14 ± 2, –32 ± 1, –18 ± 2, |
N.A | N.A | Analysis of polymer NP modified with different types of poloxamers | [255] |
| Chitosan | F-68 0.5% | 252.80 ± 7.46 | 0.40 ± 0.03 | 17.50 ± 0.93 | Doxorubicin | EE = 61.3 ± 2.28% | Fabrication of DOX-loaded pH-responsive NP for chemotherapy | [256] |
| Silk sericin | F-127 (1:5) F-87 (1:5) |
61.9 ± 5.36 103 ± 1.0 nm |
0.21 0.18 |
N.A | Inulin Paclitaxel |
EE = 65 ± 10% | Development of silk sericin NP in the presence of poloxamer for successful delivery of both hydrophobic and hydrophilic drugs | [257] |
| PLGA/F-68 | PVA 1% | 179.4 ± 11.2 | 0.309± 0.08 | −22.7 ± 5.7 | Paclitaxel | EE = 65 ± 8.3% | Development of novel PLGA:poloxamer blend NP for intravenous administration of paclitaxel | [258] |
| PLGA/F-68/F-127 | PVA, 1% | 160 ± 31 | 0.671 ± 0.03 | 18.7 ± 1.3 | Curcumin | EE = 90 ± 2.1% | Obtention of PLGA/poloxamer blend NP and evaluation of their interaction with serum proteins and its internalization ability | [259] |
| PLGA-Chitosan | F-68, 1% | 150.7 ± 1.8 | 0.16 ± 0.03 | 25.1 ± 1.6 | miR-34a | EE = 49 ± 2.1% | Anticancer treatment of multiple myeloma | [260] |
| PLGA-Chitosan | F-68, 1% | ∼130 | N.A | 30 | Anti-hTERT siRNA | N.A | Block the growth of anaplastic thyroid cancer xenograft | [261] |
| Chitosan | F-68, 10–50% | ~122 | N.A | 23.63 | Doxazosin mesylate | EE = 99.9% DL = 8.5% |
Control release and enhancing the bioavailability of doxazosin mesylate | [262] |
| PLGA | F-68, 1% | ~94 | 0.091 ± 0.010 | –0.3 | Doxorubicin | EE = 92% | Treatment of glioblastoma | [263] |
| PLGA/Chitosan | F-68, 5% | ~134.4 | N.A | 43.1 | Insulin | EE = 52.8% DL = 1.3% |
Characterization of bioadhesive NP for oral administration | [264] |
| PLGA | P-85 | 156.7 ± 3.9 | 0.21 ± 0.04 | –45.7 ± 2.9 | Doxorubicin | EE = 85.2 ± 4.1% DL = 7.3 ± 1.2% |
Treatment of leukemia | [265] |
| PLGA | P-85/PVA | 180.26 ± 5.60 | 0.184 | −17.47 ± 2.67 | Docetaxel | EE = 82.7% DL = 10% |
Breast cancer treatment | [266] |
| Chitosan-γPGA | F-127, 0.25–1% | 193.1 ± 8.9 | 0.29 ± 0.02 | 20.6 ± 2.4 | Curcumin | EE = 52.8 ± 4.7% | Wound regeneration | [267] |
| PCL | F-127, 0.06% | ∼123.5 | N.A | –29.6 | Chloramphenicol | EE = 98.3% | For treatment of MRSA-infected burn wounds | [268] |
| Folated F127/PLGA | F-127 | 107.6 ± 4.25 | 0.308 ± 0.01 | N.A | Paclitaxel | EE = 3.4% | Prolongation of the circulation time of paclitaxel | [269] |
| F-127 | F-127, 0.02% | 9.70 ± 0.31 | 0.195 ± 0.029 | –27.01 ± 0.20 | Berberine | EE = 87.6 ± 1.52% | Improve permeability and retention in the skin | [270] |
| PLGA | F-127 and F-108, 0.2% | ~115 | <0.1 | –11.3 | N.A | N.A | Functionalization of polymeric NP | [271] |
| F-127 | F-127, 1.2% | 70 ± 2.4 | 0.12 | N.A | Gossypol | EE = 91.2 ± 3.1% DL = 9.1 ± 0.42% |
Cancer drug release study | [272] |
| Trimethyl chitosan | F-127, 0.1% | ~160 | 0.140 | +20.1 | Methotrexate | EE = 93.6% DL = 8.95% |
Effective delivery of methotrexate in osteosarcoma | [273] |
| PLGA | F-127, 1% | 159.0 ± 3.0 | 0.099 ± 0.042 | –15.4 ± 0.7 | Rose Bengal | DL = 0.82 ± 0.27% | Evaluation of the effect of the nanoparticle delivery system on the biodistribution of the drug | [274] |
| PLGA/F-68 | N.A. | 154 | 0.118 | –25.2 ± 1.1 | PDGF-BB | EE = 87 ± 2% | Development of injectable controlled release device based on polymeric NP for the delivery of growth factors. | [275] |
Abbreviations: N.A. = Not Available; EE = Entrapment efficiency; DL = Drug Loading; PBCA = Poly(butyl cyanoacrylate); PCL = Poly (e-Caprolactone); PDGF-BB = platelet derived growth factor; PDI = Polidispersity Index; PLGA = Poly(lactic-co-glycolic acid); PS = Poly(styrene; F-68 = poloxamer 188; F-87 = poloxamer 238; F-108 = poloxamer 338; F-127 = poloxamer 407; L61 = poloxamer 181; L121 = poloxamer 401; P-85 = poloxamer 235.